Identifying breast cancer at the earliest possible stage has important prognostic implications: a greater number of available treatment options, increased survival rates and an improved quality of life." "ABUS combined with QVCAD provides the next crucial step in supplemental breast screening for women with dense breasts," said Bob Wang, Chairman, and CEO of QView Medical.īrian McEathron, Vice President, General Imaging Ultrasound at GE Healthcare, said, "Our goal is to support clinicians by enabling the timely, accurate diagnosis and treatment of cancer in dense breasts. The integration of QVCAD into the ABUS reading process is a breakthrough for streamlining workflow and enhancing clinical confidence. Early cancer detection is critical to increased survival rates and improved patient care and can reduce the cost of care6. Dense breasts increase cancer risk by 4-6 times5, affecting more than 40 percent of women3. Mammography misses one third of cancers in dense breasts3, and while supplemental screening finds more cancers, it requires reasonable callback and biopsy rates4. Following years of development, QVCAD, which was previously connected to the Invenia ABUS 2.0 through an external PC and server, is now allowing clinicians to access the software through the Invenia ABUS Viewer, streamlining clinical workflow with reducing reading time by up to 33%1, while improving clinical outcomes with experience up to 93% sensitivity for lesion detection2.
0 Comments
Leave a Reply. |